CRISPR biotech Intellia leases a big R&D hub in Cambridge, MA

Intellia Therapeutics, a Novartis ($NVS)-backed biotech working on gene-editing technology, leased a sizable research space in the hotbed of Cambridge, MA. As the Boston Business Journal reports, the company is taking up 65,000 square feet in a building that formerly hosted Vertex Pharmaceuticals ($VRTX). Intellia is working off of a $70 million funding round closed last year, using CRISPR technology to edit genetic code in hopes of crafting therapies for cancer and autoimmune disease. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.